The EIC Advanced Innovation Challenges are an initiative designed to accelerate strategically important breakthrough technologies. Unlike traditional research calls, these Challenges take a mission-driven, user-focused approach, bringing innovators and end-users together from the very beginning.
The goal is simple:
- Identify bold, deep-tech solutions with transformative potential
- Rapidly test their feasibility and relevance
- Fast-track the most promising ones into real-world deployment
Through a two-stage process, the scheme first supports quick technical and market validation (Stage 1) and then expands into large-scale development and testing with users (Stage 2). This makes it ideal for technologies that could reshape entire sectors if given the right boost at the right time.
In 2027, the pilot moves to a restricted Stage 2 call following the Stage 1 competition launched in 2026.
Who can apply (Stage 2)?
- Only proposals selected for funding under the 2026 Stage 1 call may proceed to the restricted Stage 2 competition, under the programme’s rules on participation and rights to the results.
- Eligible single applicants or small consortia of two or three entities can apply, subject to the relevant country and consortium conditions.
Funding (Stage 2, 2027)
- Up to €2.5 million lump-sum grant (100% of eligible costs).
- Duration: up to 2.5 years.
- Focus: real-world development, user testing, integration and deployment.
Challenge themes for the Advanced Innovation Challenges
1. Accelerating Physical AI: Embodied Intelligence for the Next Frontier of AI-Powered Robotics
This challenge targets robots that combine advanced AI with physical capability in disaster response and civil security, autonomous laboratories for scientific discovery, or personal and professional assistance. Stage 2 focuses on developing integrated systems, testing them with users in real-world settings and demonstrating progress towards TRL 6–7.
2. Translating New Approach Methodologies (NAMs) into practice
This challenge supports methods that replace, reduce or refine animal use in preclinical biomedical research and in testing medicinal products and medical technologies for safety, efficacy or quality. Examples include organoids, organ-on-chip systems and predictive computational models. Stage 2 targets functional, scalable prototypes at TRL 6, supported by benchmarking, validation outside the developer’s laboratory and engagement with industry or regulators.
Deadline Stage 2 (2027)
- 15 June 2027

This article was co-created by:

Harita Yedavally PhD
Senior Consultant

Filipa Carvalhal Marques PhD
Senior Consultant

Isa van der Veen
Consultant
